Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Gurdeep Mannu from the Nuffield Department of Population Health has won the Office for National Statistics (ONS) Research Excellence Award for a study which highlighted early risk factors for breast cancer patients.

breast examination

The study looked at more than 25 years of data on women receiving different breast cancer treatments, has been recognised by the ONS in its Research Excellence Awards for its insight and its important implications for management of patients with this kind of early-stage breast cancer in the future.   

Dr Gurdeep Mannu’s research showed that women who are diagnosed with ductal carcinoma in situ (an early-stage breast cancer) during breast screening go on to experience higher risks of developing invasive breast cancer and of death from breast cancer, compared with the general population. 

The research looked at data on 35,000 women in England diagnosed as having ductal carcinoma in situ by the NHS Breast Screening Programme from 1988 to 2014. It combined ONS mortality data with Hospital Episode Statistics from NHS Digital to show that the rate of women later developing invasive breast cancer was more than double what was expected, while mortality rates were 70% higher than expected. 

These findings will have important implications for management of patients with this kind of early-stage breast cancer in the future. 

The full story is on the Nuffield Department of Population Health website

Similar stories

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.